Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Area of Science:

• Interventional Radiology
• Hepatobiliary Oncology

Background:

• Transarterial chemoembolization (TACE) is a primary treatment for intermediate-stage hepatocellular carcinoma (HCC).
• Transfemoral access (TFA) is the conventional method for TACE.
• Transradial access (TRA) is favored in coronary interventions for its safety profile.

Purpose of the Study:

• To investigate the feasibility and outcomes of TRA for TACE.
• To compare TRA TACE with traditional TFA TACE regarding safety and efficacy.

Main Methods:

• Retrospective analysis of patients undergoing TRA TACE at a single institution.
• Evaluation of procedural success, radial artery occlusion (RAO) rates, and access site complications.
• Data collected from October 2017 to October 2018 for 112 patients and 160 procedures.

Main Results:

• High technical success rate of 95.0% (152/160) for TRA TACE.
• Low crossover rate from TRA to TFA (1.9%).
• Zero access site-related bleeding complications and a low asymptomatic RAO rate of 2.7% (3/112 patients).

Conclusions:

• TRA TACE is a safe and effective alternative to TFA TACE.
• TRA offers enhanced safety, reduced bleeding complications, and improved patient satisfaction.
• TRA is particularly beneficial for elderly patients, obese individuals, or those with high bleeding risk.